Coenzyme Q10
An antioxidant compound studied for heart failure and mitochondrial support.
Supplements
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Coenzyme Q10
An antioxidant compound studied for heart failure and mitochondrial support.
Evidence category: Clinical study. This describes the source category, not approval or certainty.
Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.
Coenzyme Q10 is a fat-soluble compound made naturally by the body and present in every cell membrane, where it functions in mitochondrial energy production and as an antioxidant. Levels are reduced in some chronic conditions, and it has been studied as an adjunctive supplement mainly in heart failure, alongside smaller studies in migraine, statin-associated muscle symptoms and fibromyalgia.
Benefits reported in the imported source
- Reduced major adverse cardiovascular events in a large randomized heart failure trial
- Generally well tolerated, with a low rate of reported side effects
- Some evidence also reported for statin-associated muscle symptoms and migraine prevention, though weaker
Risks and limits
- Strong trial evidence exists mainly for heart failure and does not necessarily generalize to other claimed uses
- Product potency and formulation vary widely between manufacturers
- Long-term outcome data outside the heart failure trial setting are limited
Source bottom line: The heart failure evidence is unusually robust for a supplement, but that same strength of evidence does not extend to most of the other uses it is marketed for.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
Patients with moderate to severe chronic heart failure enrolled in the Q-SYMBIO randomized, double-blind, multicenter trial (420 participants)
- Reported regimen
- Coenzyme Q10 100 mg three times daily added to standard heart failure therapy, compared with placebo, over a two-year prospective follow-up
- Duration
- Two-year prospective follow-up
- Reported outcome
- Fewer major adverse cardiovascular events (15 percent versus 26 percent), lower cardiovascular and all-cause mortality, and fewer heart-failure hospitalizations compared with placebo
- Source
- The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: Results From Q-SYMBIO - PubMed
Claim provenance
evidence.json#/catalog:supplement:coenzyme-q10/protocols/0
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Historical research outcome: no-verified-description · 2026-10-06
No suitable community description was independently verified in these checks. The entry remains empty; this does not establish that no practice exists elsewhere.
- https://www.nccih.nih.gov/health/coenzyme-q10: no-practice-description — This retrieved source was checked, but no suitable community description was independently verified. Research regimens, expert advice, product identity and efficacy claims were not repurposed.
- https://www.mayoclinic.org/drugs-supplements-coenzyme-q10/art-20362602: blocked — Independent direct retrieval returned HTTP 403. No description was verified from this inaccessible response.
Pharmacokinetic context
Historical half-life estimate: 30.2 hours. Mei et al. 2026, Clin Pharmacol Drug Dev, PMID 41789786 — single 240 mg oral dose, crossover; median 36.3h, range 6.8-52.6h, reflecting lipophilicity and enterohepatic recycling Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.
Source references
- The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: Results From Q-SYMBIO - PubMed
- Coenzyme Q10 - StatPearls - NCBI Bookshelf (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
Snapshot provenance
Source ID: catalog:supplement:coenzyme-q10. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.